G1 Therapeutics Stock Analysis


USD 5.77  0.19  3.19%   

The big decline in price over the last few months for G1 Therapeuticsmay raise some interest from investors. The stock closed today at a share price of 5.77 on 178,431 in trading volume. The company directors and management failed to add value to investors and position the entity supply of money to exploit market volatility in November. However, diversifying your holdings with G1 Therapeutics or similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 6.32. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the G1 Therapeutics partners.
Please check Risk vs Return Analysis.
The G1 Therapeutics stock analysis report makes it easy to digest most publicly released information about G1 Therapeutics and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. G1 Therapeutics Stock analysis module also helps to analyze the G1 Therapeutics price relationship with some important fundamental indicators such as market cap and management efficiency.

G1 Therapeutics Stock Analysis Notes

About 51.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 4.03. G1 Therapeutics had not issued any dividends in recent years. G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina. G1 Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 148 people. To learn more about G1 Therapeutics call Mark Velleca at 919 213 9835 or check out https://www.g1therapeutics.com.

G1 Therapeutics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. G1 Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding G1 Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
G1 Therapeutics generated a negative expected return over the last 90 days
G1 Therapeutics has high historical volatility and very poor performance
The company reported the previous year's revenue of 31.48 M. Net Loss for the year was (148.35 M) with profit before overhead, payroll, taxes, and interest of 29.46 M.
G1 Therapeutics currently holds about 143.96 M in cash with (132.11 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.37.
G1 Therapeutics has a poor financial position based on the latest SEC disclosures
Latest headline from news.google.com: G1 Therapeutics to Participate in the Virtual Evercore ISI HealthCONx Conference - Marketscreener.com

G1 Therapeutics Upcoming and Recent Events

Earnings reports are used by G1 Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to G1 Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report23rd of February 2022
Next Financial Report4th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End23rd of February 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

G1 Therapeutics Largest EPS Surprises

Earnings surprises can significantly impact G1 Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Fiscal Date
Estimated EPS
Reported EPS
View All Earnings Estimates

G1 Therapeutics SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. G1 Therapeutics prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that G1 Therapeutics investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial G1 Therapeutics specific information freely available to individual and institutional investors to make a timely investment decision.
3rd of August 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
27th of July 2022
Financial Statements and Exhibits. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
11th of July 2022
Unclassified Corporate Event
8th of July 2022
Unclassified Corporate Event
28th of June 2022
Financial Statements and Exhibits. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
24th of June 2022
Financial Statements and Exhibits. Submission of Matters to a Vote of Security Holders. Entry into a Material Definitive Agreement
4th of May 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
23rd of February 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition

G1 Therapeutics Thematic Classifications

In addition to having G1 Therapeutics stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Cancer Fighters
Public companies from health care and pharmaceutical sectors that are focused on fighting cancer

G1 Therapeutics Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 279.88 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate G1 Therapeutics's market, we take the total number of its shares issued and multiply it by G1 Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

G1 Therapeutics Profitablity

G1 Therapeutics' profitability indicators refer to fundamental financial ratios that showcase G1 Therapeutics' ability to generate income relative to its revenue or operating costs. If, let's say, G1 Therapeutics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, G1 Therapeutics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of G1 Therapeutics' profitability requires more research than a typical breakdown of G1 Therapeutics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2022
Return on Investment(68.49) (73.90) 
Return on Average Assets(61.47) (66.33) 
Return on Average Equity(92.46) (99.76) 
Return on Invested Capital(2.67) (2.74) 
Return on Sales(4.54) (4.89) 

Management Efficiency

The entity has return on total asset (ROA) of (0.4355) % which means that it has lost $0.4355 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (1.3725) %, meaning that it created substantial loss on money invested by shareholders. G1 Therapeutics management efficiency ratios could be used to measure how well g1 therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return on Investment is likely to drop to -73.9 in 2022. Return on Average Assets is likely to drop to -66.33 in 2022. G1 Therapeutics Total Assets Per Share are fairly stable at the moment as compared to the past year. G1 Therapeutics reported Total Assets Per Share of 5.97 in 2021. Net Current Assets as percentage of Total Assets is likely to rise to 96.04 in 2022, whereas Total Assets are likely to drop slightly above 212.9 M in 2022.
Last ReportedProjected for 2022
Book Value per Share 3.42  3.69 
Enterprise Value over EBIT(2.00) (2.16) 
Enterprise Value over EBITDA(1.82) (1.96) 
Price to Book Value 3.02  3.18 
Tangible Assets Book Value per Share 6.06  8.41 
Enterprise Value259 M321.6 M
Tangible Asset Value254.1 M242.6 M

Technical Drivers

As of the 1st of December, G1 Therapeutics owns the market risk adjusted performance of (0.58), and Standard Deviation of 6.18. G1 Therapeutics technical analysis makes it possible for you to employ past data patterns with the intention to determine a pattern that calculates the direction of the entity's future prices. Strictly speaking, you can use this information to find out if the entity will indeed mirror its model of historical prices and volume patterns, or the prices will eventually revert. We have analyze and collected data for nineteen technical drivers for G1 Therapeutics, which can be compared to its peers in the sector. Please check out G1 Therapeutics standard deviation, as well as the relationship between the value at risk and kurtosis to decide if G1 Therapeutics is priced more or less accurately, providing market reflects its prevailing price of 5.77 per share. Given that G1 Therapeutics has jensen alpha of (1.24), we strongly advise you to confirm G1 Therapeutics's latest market performance to make sure the company can sustain itself sooner or later.

G1 Therapeutics Price Movement Analysis

The output start index for this execution was three with a total number of output elements of fifty-eight. G1 Therapeutics Triple Exponential Moving Average indicator shows smoothing effect of G1 Therapeutics price series composite of a single exponential moving average, a double exponential moving average and a triple exponential moving average.

G1 Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific G1 Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on G1 Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases G1 Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Mark Velleca over a month ago via Macroaxis 
Exercise or conversion by Mark Velleca of 15000 shares of G1 Therapeutics subject to Rule 16b-3
Mark Velleca over two months ago via Macroaxis 
Exercise or conversion by Mark Velleca of 20000 shares of G1 Therapeutics subject to Rule 16b-3
Rajesh Malik over two months ago via Macroaxis 
Exercise or conversion by Rajesh Malik of 18000 shares of G1 Therapeutics subject to Rule 16b-3
Mark Velleca over three months ago via Macroaxis 
Exercise or conversion by Mark Velleca of 80000 shares of G1 Therapeutics subject to Rule 16b-3
Sharpless Norman over three months ago via Macroaxis 
Acquisition by Sharpless Norman of 60000 shares of G1 Therapeutics subject to Rule 16b-3
Rajesh Malik over three months ago via Macroaxis 
Sale by Rajesh Malik of 648 shares of G1 Therapeutics
Lee Jacks over three months ago via Macroaxis 
Acquisition by Lee Jacks of 60000 shares of G1 Therapeutics subject to Rule 16b-3
Flowers Cynthia Louise over three months ago via Macroaxis 
Acquisition by Flowers Cynthia Louise of 30000 shares of G1 Therapeutics subject to Rule 16b-3
Mark Velleca over six months ago via Macroaxis 
Exercise or conversion by Mark Velleca of 15000 shares of G1 Therapeutics subject to Rule 16b-3
Rajesh Malik over six months ago via Macroaxis 
Exercise or conversion by Rajesh Malik of 10000 shares of G1 Therapeutics subject to Rule 16b-3
Mark Velleca over a year ago via Macroaxis 
Exercise or conversion by Mark Velleca of 40000 shares of G1 Therapeutics subject to Rule 16b-3
Mark Velleca over a year ago via Macroaxis 
Sale by Mark Velleca of 10000 shares of G1 Therapeutics

G1 Therapeutics Predictive Daily Indicators

G1 Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of G1 Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

G1 Therapeutics Forecast Models

G1 Therapeutics time-series forecasting models is one of many G1 Therapeutics' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary G1 Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About G1 Therapeutics Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how G1 Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling G1 Therapeutics shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as G1 Therapeutics. By using and applying G1 Therapeutics Stock analysis, traders can create a robust methodology for identifying G1 Therapeutics entry and exit points for their positions.
Last ReportedProjected for 2022
Gross Margin 84.24  83.75 

Current G1 Therapeutics Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. G1 Therapeutics analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. G1 Therapeutics analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
G1 Therapeutics current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most G1 Therapeutics analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand G1 Therapeutics stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of G1 Therapeutics, talking to its executives and customers, or listening to G1 Therapeutics conference calls.
G1 Therapeutics Analyst Advice Details

G1 Therapeutics Stock Analysis Indicators

G1 Therapeutics stock analysis indicators help investors evaluate how G1 Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading G1 Therapeutics shares will generate the highest return on investment. By understating and applying G1 Therapeutics stock analysis, traders can identify G1 Therapeutics position entry and exit signals to maximize returns.
Begin Period Cash Flow207806000.00
Logo U R LimglogosUSGTHX.png
Common Stock Shares Outstanding37878026.00
Total Stockholder Equity143541000.00
DescriptionG1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administ
Tax Provision925000.00
Property Plant And Equipment Net9048000.00
Retained Earnings-584459000.00
Cash And Short Term Investments221186000.00
Retained Earnings Total Equity-584459000.00
Accounts Payable2897000.00
Net Debt-138131000.00
50 Day M A10.2218
Total Current Liabilities27613000.00
Currency CodeUSD
Other Operating Expenses173933000.00
Non Current Assets Total10529000.00
Common Stock Total Equity4000.00
Non Currrent Assets Other1481000.00
Please check Risk vs Return Analysis. Note that the G1 Therapeutics information on this page should be used as a complementary analysis to other G1 Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.

Complementary Tools for G1 Therapeutics Stock analysis

When running G1 Therapeutics price analysis, check to measure G1 Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy G1 Therapeutics is operating at the current time. Most of G1 Therapeutics' value examination focuses on studying past and present price action to predict the probability of G1 Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move G1 Therapeutics' price. Additionally, you may evaluate how the addition of G1 Therapeutics to your portfolios can decrease your overall portfolio volatility.
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Is G1 Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of G1 Therapeutics. If investors know G1 Therapeutics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about G1 Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
279.9 M
Quarterly Revenue Growth YOY
Return On Assets
Return On Equity
The market value of G1 Therapeutics is measured differently than its book value, which is the value of G1 Therapeutics that is recorded on the company's balance sheet. Investors also form their own opinion of G1 Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is G1 Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because G1 Therapeutics' market value can be influenced by many factors that don't directly affect G1 Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between G1 Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine G1 Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, G1 Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.